OR WAIT null SECS
August 27, 2021
The European Commission has approved UCB's treatment for adults with moderate-to-severe plaque psoriasis, BIMZELX (bimekizumab).
Insilico Biotechnology has joined the Inno4vac project—an innovative European public-private partnership aimed at accelerating vaccine R&D timelines.
August 26, 2021
Signal Rx Pharmaceuticals, Crystec, and ADYA Consulting are collaborating on the development of an inhaled dry powder formulation of SF2523 to treat pulmonary fibrosis, lung cancer, and SARS-CoV-2 related illnesses.
Aptamer Group and Bio-Works Technologies are partnering up to develop a new affinity resin for improved purification and scale-up of gene therapy vectors.
MHRA has approved Scancell’s clinical trial application for the initiation of the first-in-human Phase I/II study of Modi-1—a therapeutic vaccine candidate from the company's Moditope platform.
CC Bio has raised £890,000 (US $1.2 million) in seed funding from CMS Ventures to accelerate the development of an innovative approach to infection treatment and prevention.
August 25, 2021
AGC Biologics has broken ground on a new multipurpose facility in Copenhagen, Denmark, that will increase capacity.
August 20, 2021
MHRA has approved Moderna’s COVID-19 vaccine for use in 12–17-year-olds.
ICMRA has published a report setting out recommendations on how regulators should address the issues that the use of AI poses to global medicines regulation.
EMA has started evaluating RoActemra (tocilizumab), an anti-inflammatory medicine, as a potential treatment for hospitalized adult patients with severe COVID-19.